2026-04-13T05:01:21Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/109152025-10-24T10:33:19Zcom_2072_378070com_2072_378040col_2072_378092

2025-10-24T10:33:19Z urn:hdl:11351/10915 The elimination of hepatitis D as a public health problem: Needs and challenges Vanwolleghem, Thomas Armstrong, Paige FitzSimons, David Valckx, Sara Hendrickx, Greet Buti Ferret, Maria Hepatitis - Epidemiologia Hepatitis - Tractament Salut pública HEALTH CARE::Environment and Public Health::Public Health DISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis D Other subheadings::Other subheadings::Other subheadings::/epidemiology CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents ATENCIÓN DE SALUD::ambiente y salud pública::salud pública ENFERMEDADES::virosis::hepatitis viral humana::hepatitis D Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos Epidemiology; Hepatitis D virus; Public health Epidemiología; Virus de la hepatitis D; Salud pública Epidemiologia; Virus de l'hepatitis D; Salut Pública Infection with hepatitis D virus leads to liver disease and cancer most rapidly of all hepatitis viruses. However, knowledge about hepatitis D remains poor and the burden and impact are underestimated, even though some 12–15 million people mainly in low- and middle-income countries may be affected. Its epidemiology is changing, with increasing migration leading to increased risks of infection and disease. A recent Viral Hepatitis Prevention Board meeting reviewed the current epidemiological status, improvements in diagnostic testing, advances in the development of novel antiviral agents in phase III trials and the need for a greater public health response, such as new guidelines and recommended testing of all people newly identified as infected with hepatitis B virus for hepatitis D virus infection. It identified issues and needs for attention with regard to prevention, diagnosis and treatment. The VHPB is supported by unrestricted grants from the vaccine industry (GlaxoSmithKline Biologicals, Sanofi Pasteur, Merck and Gilead), but remains strict operational/scientific independence and editorial control. Speakers, neither board members are paid for their participation. 2025-10-24T10:33:19Z 2025-10-24T10:33:19Z 2024-01-26T11:16:21Z 2024-01-26T11:16:21Z 2024-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/10915 Journal of Viral Hepatitis;31(1) https://doi.org/10.1111/jvh.13891 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Wiley Scientia